查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836936

呼吸道感染疾病藥物市場（依治療類型、感染類型、患者類型和給藥途徑分類）－2025-2032 年全球預測

Respiratory Tract Infection Therapeutic Market by Therapeutic Type, Infection Type, Patient Type, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，呼吸道感染疾病藥物市場將成長至 858.5 億美元，複合年成長率為 7.41%。

主要市場統計數據
基準年2024年 484.3億美元
預計2025年 518.5億美元
預測年份：2032年 858.5億美元
複合年成長率（%） 7.41%

建立現代化的呼吸道感染疾病護理環境，並為臨床、監管和商業相關人員制定策略重點

由於病原體不斷演變、季節動態變化以及醫療服務模式的不斷變化，呼吸道感染疾病對臨床醫生、醫療保健系統和生物製藥申辦方構成了長期挑戰。治療方案包括小分子抗生素和抗病毒藥物、止咳藥和鼻腔祛痰藥等對症藥物，以及調節宿主反應的抗發炎藥物。本概述將當前的治療環境置於近期臨床和監管趨勢之中，並概述了相關人員為取得成功必須解決的營運和策略重點。

隨著抗生素管理的加強和精準醫療方法的普及，治療決策日益需要在快速診斷、標靶治療和以患者為中心的治療結果之間尋求平衡。同時，吸入技術、製劑科學和生物製藥的進步正在重塑治療的給藥和評估方式。這些綜合因素正在重塑臨床路徑和商業性考量，需要製定將研發、監管事務、生產和市場進入聯繫起來的整合策略。

本導言重點在於轉型變革、關稅相關供應鏈影響、關鍵細分促進因素、區域差異、競爭情報、可操作建議以及檢驗背後的嚴​​謹調查方法。讀者將獲得全面的概述，其中重點在於突出醫療保健相關人員面臨的當前營運挑戰和長期策略問題。

識別改變呼吸道感染疾病藥物和治療途徑的科學、交付、監管和商業性曲折點

在科學進步、新型給藥平台和醫療保健系統不斷變化的預期的推動下，呼吸道感染疾病藥物領域正在經歷變革時期。分子診斷和快速就地檢驗正在加速針對病原體的治療選擇，擴大抗病毒藥物的作用，並減少經驗性抗生素的使用。這種診斷-臨床反饋循環正在重塑處方行為，並為標靶治療藥物研發開闢清晰的道路。

同時，藥物傳遞領域的創新，尤其是吸入裝置和改良的口服混懸液，正在提高依從性、加快起效速度，並促進現有分子的新應用。生物製藥和宿主定向療法正在成為傳統抗生素的補充方法，有望降低嚴重發生率和住院率。法律規範正在不斷調整以適應這些治療方法，並強調真實世界證據和核准後安全監測。

商業性來看，付款人和醫療保健提供者正在優先考慮將臨床結果與報銷掛鉤的價值導向方法，並要求申辦方不僅要證明療效，還要證明以患者為中心的終點以及醫療系統資源利用率的可衡量改進。因此，臨床開發、生產和證據生成的敏捷性已成為一項競爭優勢，需要跨職能協作和對轉化科學的持續投資。

分析 2025 年關稅格局如何重塑呼吸藥物採購經濟性、供應鏈彈性和臨床可用性

近期的關稅政策將於2025年生效，這為製藥和醫療設備供應鏈帶來了新的複雜性，並對治療藥物的可近性、製造經濟性和籌資策略產生了具體影響。關稅造成的成本差異不僅最終產品，也影響原料藥、輔料和吸入裝置的專用組件。這些成本壓力迫使製造商重新評估籌資策略，優先選擇免稅地區的合格供應商，並考慮在區域內生產，以保護利潤率並確保供應的連續性。

臨床上，供應中斷或首選藥物價格突然上漲可能會改變處方模式，尤其是在急診環境中，因為治療決策對時間要求較高。醫院和醫療系統可能會調整處方，優先考慮採購管道穩定的療法，與集團採購組織的合約談判也可能擴大將關稅風險納入風險變數。對於公司而言，透明的成本模型和與付款人的主動溝通將變得越來越重要，以便協商出反映新成本結構的報銷途徑。

政策應對措施和私人緩解策略正在同步發展。企業正在加快在適用關稅的地區多元化製造能力本地化和供應商網路。策略性庫存管理和遠期採購協議提供了短期緩衝，但長期韌性將取決於靈活的生產架構、模組化製造投資以及將風險分散到不同地理位置的夥伴關係模式。整體而言，2025 年的關稅發展凸顯了對整合供應鏈智慧和自適應商業規劃的策略需求。

分析治療層級、感染部位、患者人口統計和給藥途徑，以確定差異化的臨床和商業性需求

細緻的細分框架揭示了不同治療類別和患者群體中各種需求和發展的促進因素。依照治療類型，重點介紹了抗生素、抗病毒藥物、止咳藥、鼻減充血劑和非類固醇消炎劑，並將抗生素進一步細分為Fluoroquinolones、大環內酯類、青黴素類和四環黴素，以反映其活性頻譜、抗藥性考慮和製劑策略。這些治療差異體現在開發重點、管理政策和商業性定位。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 越來越多高危險群成年人使用長效吸入式單株抗體預防呼吸道合胞呼吸道融合病毒（RSV）
  • 整合人工智慧驅動的診斷平台，用於門診早期發現多種病毒性呼吸道感染疾病
  • 在臨床試驗中擴大針對流感和新興冠狀病毒的廣譜口服抗病毒療法
  • 吸入式RNA干擾療法標靶並抑制呼吸道病毒複製，引發投資人興趣
  • 生技新興企業與成熟製藥公司之間的策略合作，開發用於病毒性支氣管擴張療法 (RTI) 的聚乙二醇干擾素
  • 增加使用智慧型手機連接的肺功能監測器來在家中即時追蹤感染進展

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 呼吸道感染疾病藥物市場（依治療類型）

  • 抗生素
    • Fluoroquinolones
    • 大環內酯類
    • 青黴素
    • 四環黴素
  • 抗病毒藥物
  • 止咳藥
  • 鼻減充血劑
  • 非類固醇消炎劑

9. 呼吸道感染疾病藥物市場（依感染類型）

  • 下呼吸道感染疾病
  • 上呼吸道感染疾病

第10章呼吸道感染疾病藥物市場（依患者類型）

  • 成人
  • 老年人
  • 孩子們

第11章呼吸道感染疾病藥物市場依給藥途徑

  • 吸入
    • 定量噴霧吸入器
    • 噴霧器
  • 口服
    • 液體懸浮液
    • 藥片
  • 腸外

第12章呼吸道感染疾病藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章呼吸道感染疾病藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章呼吸道感染疾病藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Alkem Laboratories Limited
    • AstraZeneca PLC
    • Boehringer Ingelheim GmbH
    • Cadila Healthcare Limited
    • Cipla Limited
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Glenmark Pharmaceuticals Limited
    • Hikma Pharmaceuticals PLC
    • Intas Pharmaceuticals Limited
    • Lupin Limited
    • Merck & Co., Inc.
    • Mylan Inc. by Viatris Inc.
    • Novartis International AG
    • Pfizer Inc.
    • Sanofi SA
    • Steris Healthcare Pvt. Ltd.
    • Teva Pharmaceutical Industries Ltd
Product Code: MRR-035AB9C0DAC8

The Respiratory Tract Infection Therapeutic Market is projected to grow by USD 85.85 billion at a CAGR of 7.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 48.43 billion
Estimated Year [2025] USD 51.85 billion
Forecast Year [2032] USD 85.85 billion
CAGR (%) 7.41%

Framing the contemporary respiratory tract infection therapeutic environment and establishing strategic priorities for clinical, regulatory, and commercial stakeholders

Respiratory tract infections remain a perennial challenge for clinicians, health systems, and biopharma sponsors, driven by a complex interplay of pathogen evolution, seasonal dynamics, and shifting care delivery models. The therapeutic landscape spans small-molecule antibiotics and antivirals, symptomatic agents such as cough suppressants and nasal decongestants, and anti-inflammatory therapies that modulate host response. This overview situates the current therapeutic environment within recent clinical and regulatory developments while framing the operational and strategic priorities that stakeholders must address to succeed.

As antimicrobial stewardship intensifies and precision medicine approaches gain traction, therapeutic decision-making increasingly balances rapid diagnostics, targeted therapies, and patient-centered outcomes. Concurrently, advances in inhalation technology, formulation science, and biologics are reshaping how treatments are administered and evaluated. These factors together reconfigure clinical pathways and commercial considerations, demanding integrated strategies that connect R&D, regulatory affairs, manufacturing, and market access.

This introduction sets the stage for a focused examination of transformative shifts, tariff-related supply chain implications, key segmentation drivers, regional nuances, competitive intelligence, actionable recommendations, and the methodological rigor behind the analysis. Readers will find a synthesis that highlights both immediate operational levers and longer-term strategic imperatives for therapeutic stakeholders.

Identifying the scientific, delivery, regulatory, and commercial inflection points that are remaking respiratory tract infection therapeutics and care pathways

The respiratory therapeutics landscape is undergoing a period of transformation driven by scientific advances, novel delivery platforms, and evolving health system expectations. Molecular diagnostics and rapid point-of-care testing are accelerating pathogen-specific treatment selection, which augments the role of antivirals and narrows empirical antibiotic use. This diagnostic-clinical feedback loop is reshaping prescribing behavior and creating clearer pathways for targeted therapeutic development.

At the same time, innovations in drug delivery-particularly inhalation devices and reformulated oral suspensions-are enabling improved adherence, faster onset of action, and novel indications for existing molecules. Biologics and host-directed therapies are emerging as complementary approaches to traditional antimicrobials, offering the potential to mitigate severe disease and reduce hospitalization rates. Regulatory frameworks are adapting to accommodate these modalities, with increased emphasis on real-world evidence and post-approval safety monitoring.

Commercially, payers and providers are prioritizing value-based approaches that link clinical outcomes to reimbursement, prompting sponsors to demonstrate not just efficacy but measurable improvements in patient-centric endpoints and health-system resource utilization. As a result, agility in clinical development, manufacturing, and evidence generation has become a competitive differentiator, requiring cross-functional coordination and sustained investment in translational science.

Analyzing how the 2025 tariff landscape is reshaping procurement economics, supply chain resilience, and clinical availability for respiratory therapeutics

Recent tariff policies enacted in 2025 have introduced a new layer of complexity into pharmaceutical and device supply chains, with tangible implications for therapeutic availability, manufacturing economics, and procurement strategies. Tariff-induced cost differentials affect not only finished products but also active pharmaceutical ingredients, excipients, and specialized components for inhalation devices. These cost pressures compel manufacturers to reassess sourcing strategies, prioritize supplier qualification in tariff-exempt jurisdictions, and explore in-region production to preserve margin and ensure supply continuity.

Clinically, any disruption to supply or sudden cost increases for preferred formulations can prompt shifts in prescribing patterns, particularly in acute care settings where treatment decisions are time sensitive. Hospitals and health systems may adjust formularies to favor therapeutics with stable procurement channels, while contract negotiations with group purchasing organizations will increasingly incorporate tariff exposure as a risk variable. For companies, this heightens the importance of transparent cost modeling and proactive engagement with payers to negotiate reimbursement pathways that reflect new cost structures.

Policy responses and private-sector mitigation strategies are evolving in parallel. Companies are accelerating efforts to localize manufacturing capacity in tariffs-aligned regions and to diversify supplier networks. Strategic inventory management and forward-buy agreements offer short-term buffers, but long-term resilience depends on flexible production architectures, modular manufacturing investments, and partnership models that distribute risk across geographically diverse sites. Overall, tariff developments in 2025 underscore the strategic imperative for integrated supply chain intelligence and adaptive commercial planning.

Dissecting therapeutic class, infection locus, patient demographics, and administration routes to reveal differentiated clinical and commercial imperatives

A nuanced segmentation framework reveals the varying drivers of demand and development across therapeutic and patient categories. Based on therapeutic type, attention centers on antibiotics, antivirals, cough suppressants, nasal decongestants, and non-steroidal anti-inflammatory drugs, with antibiotics further differentiated into fluoroquinolones, macrolides, penicillins, and tetracyclines to reflect spectrum of activity, resistance considerations, and formulation strategies. These therapeutic distinctions inform development priorities, stewardship policies, and commercial positioning.

Based on infection type, differentiating lower respiratory tract infections from upper respiratory tract infections clarifies clinical trial design, endpoint selection, and target populations since disease severity, hospitalization risk, and diagnostic pathways diverge significantly between these categories. Based on patient type, tailoring approaches for adults, geriatrics, and pediatrics is essential because pharmacokinetics, comorbidity profiles, and adherence behaviors vary across age cohorts, influencing dosing strategies and formulation choices.

Based on route of administration, the clinical and commercial landscapes are shaped by inhalation, oral, and parenteral options; inhalation modalities are further subdivided into metered dose inhalers and nebulizers, while oral delivery includes liquid suspensions and tablets to accommodate different patient needs and compliance realities. These route distinctions drive device partnerships, stability and excipient development, and distribution considerations. Collectively, this segmentation underscores the importance of integrated product strategies that align therapeutic class, infection locus, patient demographics, and delivery modality to optimize clinical impact and market adoption.

Unpacking how divergent regional healthcare ecosystems and regulatory environments across the Americas, Europe Middle East & Africa, and Asia-Pacific shape therapeutic adoption and market entry strategies

Regional dynamics materially influence clinical practice patterns, regulatory pathways, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems emphasize rapid diagnostics, hospital stewardship programs, and negotiated contracting structures; these conditions favor therapeutics that demonstrate measurable reductions in length of stay and clear value propositions for managed care organizations. The interplay between public procurement policies and private sector contracting requires sponsors to present flexible commercial models adapted to both institutional and outpatient settings.

In Europe, Middle East & Africa, regulatory harmonization across subregions coexists with diverse reimbursement environments, which places a premium on local evidence generation and targeted payer engagement. Countries with established antimicrobial stewardship initiatives demand robust safety and resistance mitigation data, while emerging markets within the region present opportunities for scaled access strategies by addressing affordability and supply chain constraints.

Asia-Pacific displays heterogeneity that spans advanced markets with stringent regulatory expectations to high-growth markets where access and distribution challenges persist. Rapid urbanization, varied healthcare financing models, and differing disease prevalence patterns necessitate differentiated market entry tactics, including local partnerships, adaptive pricing mechanisms, and investments in diagnostic-enabled care pathways. Adapting to these regional nuances enhances the probability of successful adoption and sustained commercial performance.

Evaluating how incumbent pharmaceutical players, innovative biotech firms, generics producers, and device specialists are shaping competition and collaboration in respiratory therapeutics

Competitive dynamics in respiratory therapeutics are characterized by a mix of large multinational firms, specialized biotechs, generics manufacturers, and device innovators, each pursuing distinct routes to clinical and commercial relevance. Established pharmaceutical companies leverage scale, broad distribution networks, and existing formulary relationships to support lifecycle management of legacy molecules and invest in next-generation delivery platforms. Meanwhile, small and mid-sized biotech firms drive innovation in novel antivirals, host-response modulators, and targeted biologics, often advancing assets through strategic partnerships or licensing agreements with larger commercial partners.

Generics and biosimilar entrants apply cost-efficiency and supply reliability as differentiators, responding to stewardship-driven pressures that favor narrow-spectrum or lower-cost options in certain clinical situations. Device manufacturers and contract development and manufacturing organizations contribute critical capabilities for inhalation technology, novel excipients, and scalable sterile production, positioning themselves as essential collaborators for sponsors seeking rapid market entry. Across the ecosystem, successful companies are those that align clinical development with pragmatic commercial strategies, demonstrate regulatory agility, and invest in real-world evidence to support differentiated value claims.

Actionable cross-functional strategies for sponsors to align development, manufacturing, and market access efforts to maximize clinical adoption and minimize supply risks

Industry leaders should prioritize integrated strategies that align R&D investments with supply chain resilience and payer-aligned evidence generation. First, accelerate development pathways that incorporate rapid diagnostics and adaptive trial designs to demonstrate therapeutic specificity and real-world clinical benefit. Doing so will enable clearer differentiation in an environment that increasingly values targeted interventions and measurable outcomes.

Second, build geographically diversified manufacturing and sourcing footprints to mitigate tariff exposure and logistical disruption. Investing in modular production capabilities and qualifying alternate suppliers reduces operational risk and supports continuity of supply, which is a critical factor for hospital and system-level adoption. Third, engage proactively with payers and health systems to co-design reimbursement frameworks that reward demonstrated improvements in clinical outcomes and resource utilization. Structured real-world evidence programs and outcomes-based contracting can bridge initial cost concerns and establish long-term reimbursement pathways.

Finally, cultivate cross-sector partnerships that combine therapeutic innovation with advanced delivery platforms and diagnostics. Collaborative models that share development risk and align commercial incentives will accelerate adoption and improve patient outcomes, while also distributing the capital burden of bringing complex therapies to market.

A rigorous mixed-methods research framework combining clinical expert insight, supply chain analysis, regulatory review, and real-world evidence triangulation to ensure robust conclusions

The research approach underpinning this analysis relies on a multi-method framework that integrates primary and secondary evidence to generate a holistic view of the respiratory therapeutics landscape. Primary inputs include structured interviews with clinical opinion leaders, supply chain executives, and payer representatives, combined with targeted surveys of prescribers and hospital procurement leads. These qualitative insights are triangulated with regulatory filings, clinical trial registries, and peer-reviewed literature to validate trends and identify emerging mechanisms of action and delivery innovations.

Complementary analyses examine manufacturing footprints, tariff schedules, and procurement practices to assess operational vulnerabilities and mitigation strategies. The methodology emphasizes transparency in source attribution, reproducibility of analytic steps, and sensitivity testing of key assumptions. Limitations are acknowledged, including the dynamic nature of policy decisions and the variability of clinical practice across jurisdictions, and the report highlights areas where ongoing surveillance and iterative evidence collection will be most valuable. This robust, mixed-methods approach ensures that conclusions are grounded in both technical expertise and practical, real-world perspectives.

Concluding synthesis that integrates scientific innovation, supply resilience, and payer-aligned evidence generation as the pillars of durable success in respiratory therapeutics

The synthesis presented across these sections emphasizes that addressing respiratory tract infections effectively requires coordinated action across scientific innovation, supply chain architecture, and payer engagement. Therapeutic success increasingly depends on the integration of diagnostics, tailored formulations, and delivery technologies that meet the needs of distinct patient cohorts while satisfying stewardship imperatives. Resilience in manufacturing and sourcing, along with adaptive commercial models, will be decisive in navigating policy-driven cost pressures and procurement shifts.

Strategic focus on evidence generation that aligns with payer priorities, paired with targeted regional strategies, will enable sponsors to translate clinical efficacy into tangible healthcare value. In turn, collaborative partnerships between innovators, device developers, and healthcare providers can accelerate patient access and improve outcomes. The concluding perspective underscores that the combination of clinical rigor, operational resilience, and commercially savvy engagement forms the foundation for sustainable success in respiratory tract infection therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of long-acting inhaled monoclonal antibodies for RSV prophylaxis in high-risk adult populations
  • 5.2. Integration of AI-driven diagnostic platforms for early detection of multi-viral respiratory infections in outpatient clinics
  • 5.3. Expansion of broad-spectrum oral antiviral therapies targeting both influenza and emerging coronaviruses in clinical trials
  • 5.4. Growing investor interest in inhalable RNA interference therapeutics for targeted suppression of respiratory virus replication
  • 5.5. Strategic collaborations between biotech startups and established pharma for development of pegylated interferons in viral RTIs
  • 5.6. Increasing use of smartphone-connected pulmonary function monitors for real-time tracking of infection progression at home

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Respiratory Tract Infection Therapeutic Market, by Therapeutic Type

  • 8.1. Antibiotics
    • 8.1.1. Fluoroquinolones
    • 8.1.2. Macrolides
    • 8.1.3. Penicillins
    • 8.1.4. Tetracyclines
  • 8.2. Antivirals
  • 8.3. Cough Suppressants
  • 8.4. Nasal Decongestants
  • 8.5. Non-Steroidal Anti-Inflammatory Drugs

9. Respiratory Tract Infection Therapeutic Market, by Infection Type

  • 9.1. Lower Respiratory Tract Infection
  • 9.2. Upper Respiratory Tract Infection

10. Respiratory Tract Infection Therapeutic Market, by Patient Type

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Respiratory Tract Infection Therapeutic Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Metered Dose Inhalers
    • 11.1.2. Nebulizers
  • 11.2. Oral
    • 11.2.1. Liquid Suspensions
    • 11.2.2. Tablets
  • 11.3. Parenteral

12. Respiratory Tract Infection Therapeutic Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Respiratory Tract Infection Therapeutic Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Respiratory Tract Infection Therapeutic Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Alkem Laboratories Limited
    • 15.3.3. AstraZeneca PLC
    • 15.3.4. Boehringer Ingelheim GmbH
    • 15.3.5. Cadila Healthcare Limited
    • 15.3.6. Cipla Limited
    • 15.3.7. F. Hoffmann-La Roche AG
    • 15.3.8. GlaxoSmithKline plc
    • 15.3.9. Glenmark Pharmaceuticals Limited
    • 15.3.10. Hikma Pharmaceuticals PLC
    • 15.3.11. Intas Pharmaceuticals Limited
    • 15.3.12. Lupin Limited
    • 15.3.13. Merck & Co., Inc.
    • 15.3.14. Mylan Inc. by Viatris Inc.
    • 15.3.15. Novartis International AG
    • 15.3.16. Pfizer Inc.
    • 15.3.17. Sanofi S.A.
    • 15.3.18. Steris Healthcare Pvt. Ltd.
    • 15.3.19. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THER